Andrew McConaghie
Senior Writer
Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Andrew McConaghie
Inovio Confirms Frontrunner Status In COVID-19 Vaccine Race, But Can It Prove Skeptics Wrong?
Its ‘virus chasing’ habits has given Inovio a bad reputation. But with backing from CEPI and Bill Gates, it has a chance to prove the doubters wrong.
J&J Spots Potential Of Fate’s Stem Cells, Signs Cancer Deal Worth Up To $3bn
Investment from Janssen helps to validate the platform developed by the San Diego-based company.
COVID-19 Vaccine Could Cost As Little As $10 A Dose, Says Janssen
Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.
Moderna Not Immune To COVID-19 Effects On Trials
Company suspends enrolment to trials as coronavirus travel restrictions bite.
Podcast: Biopharma's Moment To Deliver On Coronavirus And The People's Hope
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.
UK Biotechs Seek Government Help As Economic ‘Heart Attack’ Threatens Sector
Huge economic shock to sector could be quickly alleviated by early payment of R&D Tax Credits, says BIA.